Xiaoman Li Selected Research

3' Untranslated Regions (3' UTR)

1/2020	Corrigendum to "Pseudogene CYP4Z2P 3'UTR promotes angiogenesis in breast cancer." [Biochem. Biophys. Res. Commun. 2014 oct 24, 453(3), 545-51].
1/2020	Correction to: The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
1/2018	StarD13 3'-untranslated region functions as a ceRNA for TP53INP1 in prohibiting migration and invasion of breast cancer cells by regulating miR-125b activity.
1/2018	STARD13-correlated ceRNA network-directed inhibition on YAP/TAZ activity suppresses stemness of breast cancer via co-regulating Hippo and Rho-GTPase/F-actin signaling.
10/2017	The CCR2 3'UTR functions as a competing endogenous RNA to inhibit breast cancer metastasis.
4/2016	STARD13-correlated ceRNA network inhibits EMT and metastasis of breast cancer.
3/2016	MALAT1 induced migration and invasion of human breast cancer cells by competitively binding miR-1 with cdc42.
10/2015	CXCR4 3'UTR functions as a ceRNA in promoting metastasis, proliferation and survival of MCF-7 cells by regulating miR-146a activity.
2/2015	The 3'UTR of the pseudogene CYP4Z2P promotes tumor angiogenesis in breast cancer by acting as a ceRNA for CYP4Z1.
10/2014	Pseudogene CYP4Z2P 3'UTR promotes angiogenesis in breast cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Xiaoman Li Research Topics

Disease

26	Neoplasms (Cancer) 02/2022 - 01/2012
19	Breast Neoplasms (Breast Cancer) 01/2022 - 10/2014
7	Neoplasm Metastasis (Metastasis) 02/2022 - 10/2015
6	Carcinogenesis 01/2021 - 05/2015
5	Inflammation (Inflammations) 01/2021 - 08/2014
4	Infections 01/2021 - 08/2005
3	Genomic Instability 01/2020 - 01/2017
2	Prostatic Neoplasms (Prostate Cancer) 04/2022 - 05/2015
2	Hypoxia (Hypoxemia) 01/2022 - 01/2012
2	Fibrosis (Cirrhosis) 09/2021 - 09/2017
2	Carcinoma (Carcinomatosis) 01/2021 - 01/2021
2	Colonic Neoplasms (Colon Cancer) 01/2021 - 01/2020
2	Body Weight (Weight, Body) 01/2019 - 02/2015
2	Periapical Periodontitis (Apical Periodontitis) 12/2018 - 12/2015
2	Lung Neoplasms (Lung Cancer) 09/2017 - 01/2012
2	Alzheimer Disease (Alzheimer's Disease) 08/2013 - 11/2010
2	Human Influenza (Influenza) 09/2010 - 11/2005
1	Cognitive Dysfunction 12/2022
1	Stomach Neoplasms (Stomach Cancer) 02/2022
1	Papillary Thyroid Cancer 01/2022
1	Myopia 01/2022
1	Polyploidy 12/2021
1	Atrophy 09/2021
1	Diabetic Nephropathies (Diabetic Nephropathy) 09/2021
1	Disease Resistance 01/2021
1	Iron Metabolism Disorders 01/2021
1	Hypersensitivity (Allergy) 11/2020
1	Ovarian Neoplasms (Ovarian Cancer) 11/2020
1	Granuloma 01/2020
1	Pharyngitis (Sore Throat) 01/2020
1	Progeria (Hutchinson Gilford Syndrome) 01/2020
1	Premature Aging 01/2020

Drug/Important Bio-Agent (IBA)

11	Competitive Endogenous RNAIBA 01/2020 - 02/2015
10	3' Untranslated Regions (3' UTR)IBA 01/2020 - 10/2014
9	Proteins (Proteins, Gene)FDA Link 12/2022 - 05/2012
9	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2012
4	tanshinoneIBA 02/2022 - 05/2019
4	Biological ProductsIBA 12/2021 - 08/2013
4	Messenger RNA (mRNA)IBA 11/2020 - 04/2016
3	Estrogen ReceptorsIBA 01/2021 - 05/2016
3	Tamoxifen FDA LinkGeneric 01/2019 - 05/2016
3	VaccinesIBA 05/2012 - 08/2005
2	Amyloid (Amyloid Fibrils)IBA 12/2022 - 11/2010
2	Sirtuin 2IBA 12/2022 - 01/2021
2	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2022 - 05/2019
2	hydroxide ionIBA 01/2022 - 12/2015
2	Vitamin D FDA LinkGeneric 01/2022 - 11/2019
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 09/2021 - 10/2014
2	Sirtuin 1IBA 01/2021 - 01/2020
2	Estrogens (Estrogen)FDA Link 01/2021 - 05/2016
2	Glucose (Dextrose)FDA LinkGeneric 01/2021 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 01/2020
2	1,2- di- (4- sulfamidophenyl)- 4- butylpyrazolidine- 3,5- dione (DSB)IBA 01/2020 - 01/2019
2	CateninsIBA 01/2020 - 07/2015
2	Phosphotransferases (Kinase)IBA 01/2020 - 01/2020
2	Transcription Factors (Transcription Factor)IBA 12/2019 - 01/2017
2	ChitosanIBA 12/2018 - 09/2010
2	Capsules (Microcapsules)IBA 12/2018 - 12/2015
2	Retinaldehyde (Retinal)IBA 08/2014 - 09/2011
1	Androgen Receptors (Androgen Receptor)IBA 04/2022
1	Sorafenib (BAY 43-9006)FDA Link 02/2022
1	erastinIBA 02/2022
1	Lipid PeroxidesIBA 02/2022
1	Glutathione (Reduced Glutathione)IBA 02/2022
1	Sulfasalazine (Azulfidine)FDA LinkGeneric 02/2022
1	lipid transfer protein (glycolipid transfer protein)IBA 01/2022
1	Protons (Proton)IBA 01/2022
1	25-hydroxyvitamin DIBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	2- (4- morpholinyl)- 8- phenyl- 4H- 1- benzopyran- 4- oneIBA 01/2022
1	oxidized low density lipoproteinIBA 09/2021
1	LipidsIBA 09/2021
1	Antimitotic AgentsIBA 01/2021
1	NAD (NADH)IBA 01/2021
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2021
1	cryptotanshinoneIBA 01/2021
1	IsoflavonesIBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	Photosensitizing Agents (Photosensitizers)IBA 01/2021
1	IronIBA 01/2021
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2021
1	RNA-Binding Proteins (RNA-Binding Protein)IBA 11/2020
1	PlatinumIBA 11/2020
1	RNA (Ribonucleic Acid)IBA 11/2020
1	MTOR InhibitorsIBA 01/2020
1	prelamin AIBA 01/2020
1	LycopeneIBA 01/2020
1	Analgesics (Analgesic Drugs)IBA 01/2020
1	Anti-Bacterial Agents (Antibiotics)IBA 01/2020
1	CarcinogensIBA 01/2020
1	UbiquitinIBA 01/2020
1	Therapeutic UsesIBA 01/2020

Therapy/Procedure

11	Therapeutics 01/2022 - 05/2015
6	Drug Therapy (Chemotherapy) 01/2022 - 01/2019
3	Radiotherapy 01/2022 - 01/2017
1	Proton Therapy 01/2022
1	Heavy Ion Radiotherapy 01/2022
1	Precision Medicine 11/2021
1	Photochemotherapy (Photodynamic Therapy) 01/2021
1	Chemoprevention 01/2020